[Do results of the recent clinical trials change the place of valproate in treatment of epilepsy?].
Valproate is one of the most extensively used antiepileptic drugs with a broad spectrum of efficacy and a relatively good tolerance. Results of two recently performed clinical trials (SANAD, VIP-e) indicate that valproate should remain first-line treatment in most patients with generalized seizures, and for its high efficacy valproate should be also considered as first-line therapy in patients with focal onset seizures.